Video Experimental Relacionado
Updated: Mar 19, 2026
04:24
Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
1.4K
Tratamiento de la fatiga en la enfermedad de Parkinson
Roy G Elbers1, Henk W Berendse2, Gert Kwakkel3
1Department of Physiotherapy, University of Applied Sciences, Leiden, the Netherlands2Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, the Netherlands.
JAMA
|June 9, 2016
Resumen
La rasagilina, el modafinilo y la doxepina pueden mejorar la fatiga en la enfermedad de Parkinson sin efectos secundarios significativos. Sin embargo, la evidencia limitada significa que estos hallazgos aún no ofrecen una guía clara para el tratamiento.
Área de la Ciencia:
- Neurología
- Farmacología
- Medicina Clínica
Sus antecedentes:
- La fatiga es un síntoma común y debilitante en la enfermedad de Parkinson (EP).
- Los tratamientos efectivos para la fatiga relacionada con la EP son limitados, lo que afecta a la calidad de vida del paciente.
Objetivo del estudio:
- Identificar las intervenciones farmacológicas y no farmacológicas para la fatiga de la enfermedad de Parkinson.
- Evaluar las intervenciones para mejorar la fatiga física o mental en general.
- Evaluar las intervenciones para los efectos adversos mínimos en pacientes con EP.
Principales métodos:
- Revisión sistemática de las intervenciones farmacológicas y no farmacológicas.
- Análisis de estudios que reportan mejoría de la fatiga y eventos adversos en pacientes con enfermedad de Parkinson.
Principales resultados:
- Rasagilina, modafinilo y doxepina demostraron una asociación con la mejora de la fatiga en la enfermedad de Parkinson.
- Estos agentes no se relacionaron con un mayor riesgo de efectos adversos en la población de EP.
Conclusiones:
- Rasagilina, modafinilo y doxepina muestran potencial para el manejo de la fatiga de la enfermedad de Parkinson.
- La calidad de la evidencia actual es limitada, lo que impide recomendaciones definitivas de tratamiento.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:20Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
01:22Heart Failure VI: Adjunct Therapies
514
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
514
01:21Fatigue
982
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
982